Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 16/20 | 0.43 |
| ▸ | AXL | P30530 | 15/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870303 | 0.90 | AXL (0.35) | MERTKAXLMAPK1 | |
| SCHEMBL3462249 | 0.90 | MERTK (0.46) | MERTKAXLPIK3C3MET | |
| SCHEMBL3460453 | 0.87 | MET (0.45) | MERTKAXLPIK3C3MAPK1MET | |
| SCHEMBL3461903 | 0.85 | PIK3CD (0.48) | — | |
| SCHEMBL3461403 | 0.82 | MERTK (0.43) | MERTKAXLPIK3C3MET | |
| SCHEMBL3461547 | 0.81 | AXL (0.42) | MERTKAXLPIK3C3MAPK1MET | |
| SCHEMBL3462510 | 0.81 | MERTK (0.43) | MERTKAXLPIK3C3MAPK1MET | |
| SCHEMBL3460876 | 0.80 | MERTK (0.43) | MERTKAXLPIK3C3MAPK1MET | |
| SCHEMBL3462445 | 0.79 | PIK3CD (0.49) | — | |
| SCHEMBL3462300 | 0.77 | PIK3CD (0.50) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | MERTK 833/4885AXL 895/4885PIK3C3 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.